Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine
- ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
- Richard Rheingans Ph.D., Department Chair (Creator)
- Institution
- Appalachian State University (ASU )
- Web Site: https://library.appstate.edu/
Abstract: We evaluated the cost-effectiveness of rotavirus vaccination in Uzbekistan from the healthcare system and societal perspectives. Disease burden was estimated using national statistics on hospitalizations and deaths, and international estimates of under-?ve mortality. Without vaccination, the risk for rotavirus hospitalization by age 5 is 10 per 1000 children. Rotavirus hospitalizations cost US$ 406,000 annually, of which US$ 360,000 (89%) is for medical expenses and US$ 46,000 (11%) is for non-medical and indirect costs. Rotavirus mortality rate at 0.7 per 1000 derived from national data was three-fold lower than the same rate calculated from international estimates of under-?ve mortality. Rotavirus vaccination could reduce hospitalizations and deaths by 91% and avert US$ 370,000 in hospitalization costs alone. Vaccination would be cost-effective with vaccine prices in a range of US$ 2–25 per child. However, the cost-effectiveness is greatly in?uenced by mortality, vaccine price and vaccine ef?cacy.
Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine
PDF (Portable Document Format)
185 KB
Created on 12/7/2016
Views: 723
Additional Information
- Publication
- R. Rheingans, E.T. Isakbaeva, E. Musabaev, L. Antil, R. Juraev,R.I. Glassand J.S. Bresee (2006) "Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine" Vaccine 25(2) pp. 373-380. Version of Record Available From www.sciencedirect.com
- Language: English
- Date: 2006
- Keywords
- Rotavirus, Vaccine, Cost-effectiveness